This report represents Toledo Community Hospital Oncology Program's responses to Charting Impact, a joint project of BBB Wise Giving Alliance, GuideStar USA Inc, and Independent Sector. Charting Impact uses five simple yet powerful questions to encourage strategic thinking and help organizations share concise information about their plans and progress toward impact.

**Mission:**

The Toledo Community Oncology Program (TCOP) brings compassionate and gold standard of cancer care to individuals close to home. This non-profit organization, founded in 1986, is one of the original Community Clinical Oncology Programs (CCOP) funded by the National Cancer Institute. TCOP administers Phase II, Phase III, and Phase IV cancer clinical trials from these research groups: the Alliance For Clinical Trials in Oncology (consists of the North Central Cancer Treatment Group (NCCTG), the American College of Surgeons Oncology Group (ACSG), and the Cancer and Leukemia Group B (CLGB)), NRG (consists of the National Surgical Adjuvant Breast and Bowel Project (NSAPB), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG)), the Eastern Cooperative Oncology Group (ECOG), SunCoast, and the Cancer Trials Support Unit (CTSU). Alliance For Clinical Trials in Oncology (consists of the North Central Cancer Treatment Group (NCCTG), Eastern Cooperative ...
The content of this Charting Impact Report is the sole product and responsibility of Toledo Community Hospital Oncology Program. This report does not in any way represent an endorsement from Independent Sector, BBB Wise Giving Alliance, or GuideStar, nor does it represent fulfillment of the BBB Wise Giving Alliance's Standards for Charity Accountability. For more information on Charting Impact, visit www.guidestar.org/chartingimpact
1. What are we aiming to accomplish?

The Toledo Community Oncology Program's aim is to expand cancer clinical trial availability and participation in the tri-state area, so all residents can receive the best available cancer care close to home, regardless of race, age, education level, or socioeconomic status.

2. What are our strategies for making this happen?

A concerted outreach effort to educate oncologists, primary care and referring physicians, healthcare staff and administrators is needed to expand cancer clinical trial availability at more healthcare facilities in our service area. Raising community awareness of the benefits of clinical trials and educating people about clinical trial options before they or their loved one receive a devastating diagnosis is just as important. These two education and outreach initiatives will help ensure all of those touched by cancer benefit from the latest advances in cancer care.

3. What are our organization's capabilities for doing this?

The Toledo Community Oncology Program's Executive Director Pamela Shoup and Director of Development and Communications Deb Boyce are reaching out to healthcare facilities in the region. A newly formed Clinical Research Committee, led by TCOP’s Principal Investigator Rex Mowat, MD, and comprised of physician investigators from the University of Toledo Medical Center, and the region’s two largest healthcare providers, Mercy and ProMedica health systems, are working together to strategically expand cancer clinical trial availability, access, awareness, and accrual across the tri-state region.

4. How will we know if we're making progress?

The Toledo Community Oncology's success will be measured by increasing numbers of affiliated healthcare sites, physician investigators, and clinical trial participants. Nearly half of all practicing medical, surgical and radiation oncologists in TCOP's service area are currently TCOP investigators. As clinical trial availability expands, clinical trial participation is expected to increase as well.

5. What have and haven't we accomplished so far?

The Toledo Community Oncology Program is one of the original 27 clinical research programs, fully-funded by the National Cancer Institute (NCI) since 1983, under the auspices of the National Institute for Health. Nationally, TCOP is recognized for maintaining a strong record of clinical trial patient accrual and is considered to be one of the top accruing programs in the country by our research bases. Because TCOP offers Phase II, III, and IV clinical trials, participants are assured of receiving the best standard of cancer care available. NCI grant funding is no longer sufficient to underwrite the need for cancer care in our 33-county, tri-state service area. New funding sources will expand the reach and impact of TCOP’s clinical trial program.